A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Alzheimer's disease; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 30 Apr 2024 Status changed from active, no longer recruiting to completed.
- 27 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2023 Planned End Date changed from 23 Apr 2024 to 28 Mar 2024.